protein

Recombinant Human 2'-5' Oligoadenylate Synthetase 1

MBS143683

0.002 mg

140 USD

Recombinant Protein

Recombinant Human 2'-5' Oligoadenylate Synthetase 1

2'-5' Oligoadenylate Synthetase 1

OAS1 Human; 2'-5' Oligoadenylate Synthetase 1 Human Recombinant; 2'-5'-oligoadenylate synthetase 1; (2-5')oligo(A) synthetase 1; 2-5A synthetase 1; p46/p42 OAS; E18/E16; OAS1; OIAS; IFI-4; OIASI

2'-5'-oligoadenylate synthase 1 isoform 3; 2'-5'-oligoadenylate synthase 1; 2'-5'-oligoadenylate synthase 1; (2-5')oligo(A) synthase 1; (2-5')oligo(A) synthetase 1; 2',5'-oligo A synthetase 1; 2',5'-oligoadenylate synthetase 1, 40/46kDa; 2'-5' oligoadenylate synthetase 1 p48 isoform; 2'-5' oligoadenylate synthetase 1 p52 isoform; 2'-5'-oligoisoadenylate synthetase 1; 2-5A synthase 1; 2-5A synthetase 1; E18/E16; p46/p42 OAS; 2'-5'-oligoadenylate synthetase 1, 40/46kDa; E18/E16; p46/p42 OAS

OAS1

OAS1; OAS1; OIAS; IFI-4; OIASI; OIAS; (2-5')oligo(A) synthase 1; 2-5A synthase 1

OAS1_HUMAN

E Coli

414

MGSSHHHHHH SSGLVPRGSH MMDLRNTPAK SLDKFIEDYL LPDTCFRMQI NHAIDIICGF LKERCFRGSS YPVCVSKVVK GGSSGKGTTL RGRSDADLVV FLSPLTTFQD QLNRRGEFIQ EIRRQLEACQ RERAFSVKFE VQAPRWGNPR ALSFVLSSLQ LGEGVEFDVL PAFDALGQLT GSYKPNPQIY VKLIEECTDL QKEGEFSTCF TELQRDFLKQ RPTKLKSLIR LVKHWYQNCK KKLGKLPPQY ALELLTVYAW ERGSMKTHFN TAQGFRTVLE LVINYQQLCI YWTKYYDFKN PIIEKYLRRQ LTKPRPVILD PADPTGNLGG GDPKGWRQLA QEAEAWLNYP CFKNWDGSPV SSWILLVRPP ASSLPFIPAP LHEA.

Greater than 95.0% as determined by SDS-PAGE.

The OAS1 solution contains 20mM Tris-HCl buffer (pH 8.0), 10% glycerol and 1mM DTT. Sterile Filtered colorless solution.

OAS1 although stable 4 degree C for 4 weeks, should be stored desiccated below -18 degree C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please prevent freeze-thaw cycles.

ENZYMES; Enzymes; Synthetase

Description: OAS1 Human Recombinant fused with 20 amino acid His tag at N-terminus produced in E Coli is a single, non-glycosylated, polypeptide chain containing 384 amino acids (1-364 a.a.) and having a molecular mass of 43.9kDa.The OAS1 is purified by proprietary chromatographic techniques. Introduction: OAS1 enzyme is a member of the 2',5'-oligoadenylate synthetase family. OAS1 is induced by interferons and uses adenosine triphosphate in 2'-specific nucleotidyl transfer reactions to synthesize 2',5'-oligoadenylates(2-5As). These molecules in turn activate latent RNase L resulting in viral RNA degradation and the inhibition of viral replication. OAS1 may have a role in mediating resistance to virus infection, control of cell growth, differentiation, and apoptosis. OAS1 binds double-stranded RNA and polymerizes ATP into PPP (A2'P5'A)N oligomers, which activate the latent RNase L that, once activated, cleaves single-stranded RNAs. OAS1 gene mutations are been linked to host susceptibility to viral infection. OSA1 gene polymorphisms are linked to the outcome of hepatitis C virus infection. Furthermore, OAS1 gene polymorphisms are linked to the susceptibility to severe acute respiratory syndrome.

74229015

NP_001027581.1

NM_001032409.1

P00973

43,944 Da

Cytokine Signaling In Immune System Pathway (366171); Hepatitis C Pathway (173973); Hepatitis C Pathway (173907); Herpes Simplex Infection Pathway (377873); Herpes Simplex Infection Pathway (377865); Immune System Pathway (106386); Influenza A Pathway (217173); Influenza A Pathway (217150); Interferon Signaling Pathway (187103); Interferon Alpha/beta Signaling Pathway (187104)

This gene encodes a member of the 2-5A synthetase family, essential proteins involved in the innate immune response to viral infection. The encoded protein is induced by interferons and uses adenosine triphosphate in 2'-specific nucleotidyl transfer reactions to synthesize 2',5'-oligoadenylates (2-5As). These molecules activate latent RNase L, which results in viral RNA degradation and the inhibition of viral replication. The three known members of this gene family are located in a cluster on chromosome 12. Mutations in this gene have been associated with host susceptibility to viral infection. Alternatively spliced transcript variants encoding different isoforms have been described. [provided by RefSeq, Jul 2008]

OAS1: Interferon-induced, dsRNA-activated antiviral enzyme which plays a critical role in cellular innate antiviral response. In addition, it may also play a role in other cellular processes such as apoptosis, cell growth, differentiation and gene regulation. Synthesizes higher oligomers of 2 -5 -oligoadenylates (2-5A) from ATP which then bind to the inactive monomeric form of ribonuclease L (RNase L) leading to its dimerization and subsequent activation. Activation of RNase L leads to degradation of cellular as well as viral RNA, resulting in the inhibition of protein synthesis, thus terminating viral replication. Can mediate the antiviral effect via the classical RNase L-dependent pathway or an alternative antiviral pathway independent of RNase L. The secreted form displays antiviral effect against vesicular stomatitis virus (VSV), herpes simplex virus type 2 (HSV-2), and encephalomyocarditis virus (EMCV) and stimulates the alternative antiviral pathway independent of RNase L. Belongs to the 2-5A synthase family. 4 isoforms of the human protein are produced by alternative splicing. Protein type: EC 2.7.7.84; Transferase. Chromosomal Location of Human Ortholog: 12q24.2. Cellular Component: mitochondrion; endoplasmic reticulum; cytoplasm; extracellular region; nucleus; cytosol. Molecular Function: protein binding; zinc ion binding; metal ion binding; double-stranded RNA binding; ATP binding; 2 -5 -oligoadenylate synthetase activity. Biological Process: negative regulation of viral genome replication; cytokine and chemokine mediated signaling pathway; response to virus; glucose metabolic process; purine nucleotide biosynthetic process; glucose homeostasis; defense response to virus; protein oligomerization. Disease: Diabetes Mellitus, Insulin-dependent

0.002 mg

140 USD

0.01 mg

205

1 mg

4630